Autolus Therapeutics posts strong Q3 revenue, raises full‑year guidance but misses EPS
Autolus Therapeutics reported third‑quarter 2026 net product revenue of about $41.2 million, a 95 % year‑over‑year increase, and lifted its full‑year AUCATZYL revenue outlook to at least $150 million. Gross margins turned positive at 57 % in the quarter. GAAP earnings per share were –$0.21, missing consensus estimates, while the company said it will have cash to fund operations into the second quarter of 2028.
Why it matters
The raised revenue guidance suggests higher cash generation for the remainder of 2026 (the company expects to fund operations into Q2 2028). However, the earnings miss highlights that the firm remains loss‑making and may pressure the stock price.
Key facts
- 1Q3 2026 net product revenue was $41.2 million, up 95 % YoY. investing.com
- 2GAAP EPS for the quarter was –$0.21, missing consensus estimates. seekingalpha.com
- 3The company raised its full‑year 2026 AUCATZYL net product revenue guidance to at or above $150 million. seekingalpha.com
- 4Gross margin for Q3 2026 was 57 %. investing.com
- 5Operating loss narrowed to $43.5 million versus $71.6 million a year earlier. finance.yahoo.com
- 6The commercial network expanded to 90 authorized U.S. treatment centers, exceeding the 80‑center target. investing.com
Open questions
- Material 1 says the EPS miss was $0.03, while material 2 reports a $0.05 miss for the same GAAP EPS figure.
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.